These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11426792)

  • 21. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience.
    Qureshi AI; Suri MF; Khan J; Fessler RD; Guterman LR; Hopkins LN
    Neurosurgery; 2000 Jun; 46(6):1316-24; discussion 1324-5. PubMed ID: 10834637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab.
    Qureshi AI; Suri MF; Ali Z; Kim SH; Lanzino G; Fessler RD; Ringer AJ; Guterman LR; Hopkins LN
    Neurosurgery; 2002 Mar; 50(3):466-73; discussion 473-5. PubMed ID: 11841713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abciximab readministration: results of the ReoPro Readministration Registry.
    Tcheng JE; Kereiakes DJ; Lincoff AM; George BS; Kleiman NS; Sane DC; Cines DB; Jordan RE; Mascelli MA; Langrall MA; Damaraju L; Schantz A; Effron MB; Braden GA
    Circulation; 2001 Aug; 104(8):870-5. PubMed ID: 11514371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
    Mukherjee D; Chew DP; Robbins M; Yadav JS; Raymond RE; Moliterno DJ
    J Thromb Thrombolysis; 2001 Apr; 11(2):151-4. PubMed ID: 11406730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment.
    Vahdat B; Canavy I; Fourcade L; Garcia E; Quilici J; Bonnet JL; Bory M
    Catheter Cardiovasc Interv; 2000 Feb; 49(2):177-80. PubMed ID: 10642768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
    Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Readministration of abciximab: interim report of the ReoPro readministration registry.
    Tcheng JE; Kereiakes DJ; Braden GA; Jordan RE; Mascelli MA; Langrall MA; Effron MB
    Am Heart J; 1999 Jul; 138(1 Pt 2):S33-8. PubMed ID: 10385789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alveolar hemorrhage as a complication of treatment with abciximab.
    Kalra S; Bell MR; Rihal CS
    Chest; 2001 Jul; 120(1):126-31. PubMed ID: 11451827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No.
    Ragosta M; Sarembock IJ
    J Thromb Haemost; 2004 Jan; 2(1):10-2. PubMed ID: 14717959
    [No Abstract]   [Full Text] [Related]  

  • 31. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
    Kleiman NS
    Am J Cardiol; 1997 Aug; 80(4A):29B-33B. PubMed ID: 9291243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Lazar J; Cavusoglu E
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):214-21. PubMed ID: 19156882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Adjuvant therapy with a glycoprotein IIb-IIa inhibitor (abciximab) in coronary angioplasties with a high thrombotic risk].
    Matos V; Marques AM; Oliveira H; Ramos D; Lopes P; Camacho M; Gonsalves A
    Rev Port Cardiol; 1998 Dec; 17(12):1001-5. PubMed ID: 9973861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.
    Ali A; Patil S; Grady KJ; Schreiber TL
    Catheter Cardiovasc Interv; 2000 Feb; 49(2):181-4. PubMed ID: 10642769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.